Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis

Tarang Sharma; Ashna Gupta; Ravi Chauhan; Ajaz A. Bhat; Sabah Nisar; Sheema Hashem; Sabah Akhtar; Aamir Ahmad; Mohammad Haris; Mayank Singh; Shahab Uddin

doi:10.1007/s10555-022-10026-6

journal article Open Access May 05, 2022

Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis

Tarang Sharma Ashna Gupta Ravi Chauhan Ajaz A. Bhat

Sabah Nisar Sheema Hashem Sabah Akhtar Aamir Ahmad Mohammad Haris

Mayank Singh Shahab Uddin

Cancer and Metastasis Reviews Vol. 41 No. 2 pp. 281-299 · Springer Science and Business Media LLC

View at Publisher Save 10.1007/s10555-022-10026-6

Abstract

AbstractEsophageal cancer (EC) is frequently considered a lethal malignancy and is often identified at a later stage. It is one of the major causes of cancer-related deaths globally. The conventional treatment methods like chemotherapy, radiotherapy, and surgery offer limited efficacy and poor clinical outcome with a less than 25% 5-year survival rate. The poor prognosis of EC persists despite the growth in the development of diagnostic and therapeutic modalities to treat EC. This underlines the need to elucidate the complex molecular mechanisms that drive esophageal oncogenesis. Apart from the role of the tumor microenvironment and its structural and cellular components in tumorigenesis, mounting evidence points towards the involvement of the esophageal microbiome, inflammation, and their cross-talk in promoting esophageal cancer. The current review summarizes recent research that delineates the underlying molecular mechanisms by which the microbiota and inflammation promote the pathophysiology of esophageal cancer, thus unraveling targets for potential therapeutic intervention.

Topics

No keywords indexed for this article. Browse by subject →

References

172

[1]

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249.

[2]

Arnold, M., Ferlay, J., van HenegouwenB, M. I., & Soerjomataram, I. (2020). Global burden of oesophageal and gastric cancer by histology and subsite in 2018. Gut., 69(9), 1564–71. 10.1136/gutjnl-2020-321600

[3]

Lagergren, J., Smyth, E., Cunningham, D., & Lagergren, P. (2017). Oesophageal cancer. Lancet (London, England), 390(10110), 2383–2396. 10.1016/s0140-6736(17)31462-9

[4]

Prabhu, A., Obi, K. O., & Rubenstein, J. H. (2014). The synergistic effects of alcohol and tobacco consumption on the risk of esophageal squamous cell carcinoma: A meta-analysis. American Journal of Gastroenterology, 109(6), 822–827. 10.1038/ajg.2014.71

[5]

Qu, X., Ben, Q., & Jiang, Y. (2013). Consumption of red and processed meat and risk for esophageal squamous cell carcinoma based on a meta-analysis. Annals of Epidemiology, 23(12), 762-770.e1. 10.1016/j.annepidem.2013.09.003

[6]

Chen, Y., Tong, Y., Yang, C., Gan, Y., Sun, H., Bi, H., et al. (2015). Consumption of hot beverages and foods and the risk of esophageal cancer: A meta-analysis of observational studies. BMC Cancer, 2(15), 449. 10.1186/s12885-015-1185-1

[7]

Wu, C., Wang, Z., Song, X., Feng, X.-S., Abnet, C. C., He, J., et al. (2014). Joint analysis of three genome-wide association studies of esophageal squamous cell carcinoma in Chinese populations. Nature Genetics, 46(9), 1001–1006. 10.1038/ng.3064

[8]

Ahn, J., Chen, C. Y., & Hayes, R. B. (2012). Oral microbiome and oral and gastrointestinal cancer risk. Cancer Causes Control CCC., 23(3), 399–404. 10.1007/s10552-011-9892-7

[9]

Menya, D., Maina, S. K., Kibosia, C., Kigen, N., Oduor, M., Some, F., et al. (2019). Dental fluorosis and oral health in the African Esophageal Cancer Corridor: Findings from the Kenya ESCCAPE case–control study and a pan-African perspective. International Journal of Cancer, 145(1), 99–109. 10.1002/ijc.32086

[10]

Ekheden, I., Yang, X., Chen, H., Chen, X., Yuan, Z., Jin, L., et al. (2020). Associations between gastric atrophy and its interaction with poor oral health and the risk for esophageal squamous cell carcinoma in a high-risk region of China: A population-based case-control study. American Journal of Epidemiology, 189(9), 931–941. 10.1093/aje/kwz283

[11]

Lagergren, J., & Lagergren, P. (2013). Recent developments in esophageal adenocarcinoma. CA: A Cancer Journal for Clinicians, 63(4), 232–248.

[12]

Bhat, A. A., Lu, H., Soutto, M., Capobianco, A., Rai, P., Zaika, A., et al. (2018). Exposure of Barrett’s and esophageal adenocarcinoma cells to bile acids activates EGFR-STAT3 signaling axis via induction of APE1. Oncogene, 37(46), 6011–6024. 10.1038/s41388-018-0388-8

[13]

Kauer, W. K., Peters, J. H., DeMeester, T. R., Ireland, A. P., Bremner, C. G., & Hagen, J. A. (1995). Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. The need for surgical therapy re-emphasized. Annals of Surgery, 222(4), 525–31. discussion 531-533. 10.1097/00000658-199522240-00010

[14]

Song, S., Guha, S., Liu, K., Buttar, N. S., & Bresalier, R. S. (2007). COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signalling pathways in Barrett’s oesophagus and oesophageal adenocarcinoma. Gut, 56(11), 1512–1521. 10.1136/gut.2007.121244

[15]

Peng, D., Zaika, A., Que, J., & El-Rifai, W. (2021). The antioxidant response in Barrett’s tumorigenesis: A double-edged sword. Redox Biology, 41, 101894. 10.1016/j.redox.2021.101894

[16]

Kubo, N., Morita, M., Nakashima, Y., Kitao, H., Egashira, A., Saeki, H., et al. (2014). Oxidative DNA damage in human esophageal cancer: Clinicopathological analysis of 8-hydroxydeoxyguanosine and its repair enzyme. Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus, 27(3), 285–293. 10.1111/dote.12107

[17]

Radojicic, J., Zaravinos, A., & Spandidos, D. A. (2012). HPV, KRAS mutations, alcohol consumption and tobacco smoking effects on esophageal squamous-cell carcinoma carcinogenesis. International Journal of Biological Markers, 27(1), 1–12. 10.5301/jbm.2011.8737

[18]

Oral Microbiome Composition Reflects Prospective Risk for Esophageal Cancers

Jing Wu, Zhiheng Pei, Liying Yang et al.

Cancer Research 2017 10.1158/0008-5472.can-17-1296

[19]

Smoking and microbiome in oral, airway, gut and some systemic diseases

Chunrong Huang, Guochao Shi

Journal of Translational Medicine 2019 10.1186/s12967-019-1971-7

[20]

Macgregor, I. D. (1989). Effects of smoking on oral ecology. A review of the literature. Clinical Preventive Dentistry, 11(1), 3–7.

[21]

Nociti, F. H., Jr., Casati, M. Z., & Duarte, P. M. (2015). Current perspective of the impact of smoking on the progression and treatment of periodontitis. Periodontology 2000, 67(1), 187–210. 10.1111/prd.12063

[22]

Wang, M., Li, Y., Xiao, Y., Yang, M., Chen, J., Jian, Y., et al. (2021). Nicotine-mediated OTUD3 downregulation inhibits VEGF-C mRNA decay to promote lymphatic metastasis of human esophageal cancer. Nature Communications, 12(1), 7006. 10.1038/s41467-021-27348-8

[23]

Quante, M., Bhagat, G., Abrams, J. A., Marache, F., Good, P., Lee, M. D., et al. (2012). Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell, 21(1), 36–51. 10.1016/j.ccr.2011.12.004

[24]

Liying, Y., Xiaohua, L., Carlos, W.N., Fritz, F., Richard, M.P., Zhiheng, P. (2009). Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology [Internet]. [cited 2022 Jan 4];137(2). Available from: https://pubmed.ncbi.nlm.nih.gov/19394334/ 10.1053/j.gastro.2009.04.046

[25]

Yang, L., Francois, F., & Pei, Z. (2012). Molecular Pathways: Pathogenesis and Clinical Implications of Microbiome Alteration in Esophagitis and Barrett Esophagus. Clinical Cancer Research, 18(8), 2138–2144. 10.1158/1078-0432.ccr-11-0934

[26]

Macfarlane, S., Furrie, E. ,Macfarlane, G. T.,Dillon, J. F. (2007). Microbial colonization of the upper gastrointestinal tract in patients with Barrett’s esophagus. Clin Infect Dis Off Publ Infect Dis Soc Am [Internet]. [cited 2022 Jan 4];45(1). Available from: https://pubmed.ncbi.nlm.nih.gov/17554697/ 10.1086/518578

[27]

Janmaat, M. L., Gallegos-Ruiz, M. I., Rodriguez, J. A., Meijer, G. A., Vervenne, W. L., Richel, D. J., et al. (2006). Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol Off J Am Soc Clin Oncol., 24(10), 1612–1619. 10.1200/jco.2005.03.4900

[28]

Khalafi, S., Lockhart, A. C., Livingstone, A. S., & El-Rifai, W. (2020). Targeted molecular therapies in the treatment of esophageal adenocarcinoma, are we there yet? Cancers, 12(11), E3077. 10.3390/cancers12113077

[29]

Dutton, S. J., Ferry, D. R., Blazeby, J. M., Abbas, H., Dahle-Smith, A., Mansoor, W., et al. (2014). Gefitinib for oesophageal cancer progressing after chemotherapy (COG): A phase 3, multicentre, double-blind, placebo-controlled randomised trial. The lancet Oncology, 15(8), 894–904. 10.1016/s1470-2045(14)70024-5

[30]

Kato, K., Doi, T., Kojima, T., Hara, H., Takahashi, S., Muro, K., et al. (2017). Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303). Journal of Clinical Oncology, 35(15_suppl), 4069–4069. 10.1200/jco.2017.35.15_suppl.4069

[31]

Bhatt, A. P., Redinbo, M. R., & Bultman, S. J. (2017). The role of the microbiome in cancer development and therapy. CA: A Cancer Journal for Clinicians, 67(4), 326–344.

[32]

Abdul Rahman, R., Lamarca, A., Hubner, R. A., Valle, J. W., & McNamara, M. G. (2021). The microbiome as a potential target for therapeutic manipulation in pancreatic cancer. Cancers, 13(15), 3779. 10.3390/cancers13153779

[33]

Yi, M., Jiao, D., Qin, S., Chu, Q., Li, A., & Wu, K. (2019). Manipulating gut microbiota composition to enhance the therapeutic effect of cancer immunotherapy. Integrative Cancer Therapies, 13(18), 1534735419876351. 10.1177/1534735419876351

[34]

Microenvironmental regulation of tumor progression and metastasis

Daniela F Quail, Johanna A Joyce

Nature Medicine 2013 10.1038/nm.3394

[35]

Ponomarev, A. V., & Shubina, I. Z. (2019). Insights into mechanisms of tumor and immune system interaction: Association with wound healing. Frontiers in Oncology, 9, 1115. 10.3389/fonc.2019.01115

[36]

Inflammation and cancer: back to Virchow?

Fran Balkwill, Alberto Mantovani

The Lancet 2001 10.1016/s0140-6736(00)04046-0

[37]

Blank, S., Deck, C., Dreikhausen, L., Weichert, W., Giese, N., Falk, C., et al. (2015). Angiogenic and growth factors in gastric cancer. Journal of Surgical Research, 194(2), 420–429. 10.1016/j.jss.2014.11.028

[38]

Wilson, J., & Balkwill, F. (2002). The role of cytokines in the epithelial cancer microenvironment. Seminars in Cancer Biology, 12(2), 113–120. 10.1006/scbi.2001.0419

[39]

Bhat, A. A., Nisar, S., Maacha, S., Carneiro-Lobo, T. C., Akhtar, S., Siveen, K. S., et al. (2021). Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy. Molecular Cancer, 20(1), 2. 10.1186/s12943-020-01294-3

[40]

Durand, R. E. (1991). Keynote address: The influence of microenvironmental factors on the activity of radiation and drugs. International Journal of Radiation Oncology Biology Physics, 20(2), 253–258. 10.1016/0360-3016(91)90100-i

[41]

Lee, H.-J., Zhuang, G., Cao, Y., Du, P., Kim, H.-J., & Settleman, J. (2014). Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell, 26(2), 207–221. 10.1016/j.ccr.2014.05.019

[42]

Nisar, S., Hashem, S., Macha, M. A., Yadav, S. K., Muralitharan, S., Therachiyil, L., et al. (2020). Exploring Dysregulated Signaling Pathways in Cancer. Current Pharmaceutical Design, 26(4), 429–445. 10.2174/1381612826666200115095937

[43]

Zhang, Q., Zhang, C., He, J., Guo, Q., Hu, D., Yang, X., et al. (2015). STAT3 inhibitor stattic enhances radiosensitivity in esophageal squamous cell carcinoma. Tumor Biology, 36(3), 2135–2142. 10.1007/s13277-014-2823-y

[44]

Hatata, T., Higaki, K., Tatebe, S., Shomori, K., & Ikeguchi, M. (2012). Immunohistochemical study of nuclear factor-κB expression in esophageal squamous cell carcinoma: Prognostic significance and sensitivity to treatment with 5-FU. Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus, 25(8), 716–722. 10.1111/j.1442-2050.2011.01308.x

[45]

Ogura, M., Takeuchi, H., Kawakubo, H., Nishi, T., Fukuda, K., Nakamura, R., et al. (2013). Clinical significance of CXCL-8/CXCR-2 network in esophageal squamous cell carcinoma. Surgery, 154(3), 512–520. 10.1016/j.surg.2013.06.013

[46]

Angiogenesis in life, disease and medicine

Peter Carmeliet

Nature 2005 10.1038/nature04478

[47]

Aguilar-Cazares, D., Chavez-Dominguez, R., Carlos-Reyes, A., Lopez-Camarillo, C., Hernadez de la Cruz, O. N., & Lopez-Gonzalez, J. S. (2019). Contribution of angiogenesis to inflammation and cancer. Frontiers in Oncology, 9, 1399. 10.3389/fonc.2019.01399

[48]

Shimada, H., Takeda, A., Nabeya, Y., Okazumi, S. I., Matsubara, H., Funami, Y., et al. (2001). Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer, 92(3), 663–669. 10.1002/1097-0142(20010801)92:3<663::aid-cncr1368>3.0.co;2-l

[49]

Nguyen, G. H., Schetter, A. J., Chou, D. B., Bowman, E. D., Zhao, R., Hawkes, J. E., et al. (2010). Inflammatory and microRNA gene expression as prognostic classifier of Barrett’s-associated esophageal adenocarcinoma. Clinical Cancer Research: Official Journal of the American Association for Cancer Research, 16(23), 5824–5834. 10.1158/1078-0432.ccr-10-1110

[50]

Cao, W., Peters, J. H., Nieman, D., Sharma, M., Watson, T., & Yu, J. (2015). Macrophage subtype predicts lymph node metastasis in oesophageal adenocarcinoma and promotes cancer cell invasion in vitro. British Journal of Cancer, 113(5), 738–746. 10.1038/bjc.2015.292

Showing 50 of 172 references

Cited By

60

A generalizable cross-continent prediction of esophageal squamous cell carcinoma using the oral microbiome

Shahd ElNaggar, Wenlong Carl Chen · 2026

Communications Medicine

Metrics

60

Citations

172

References

Details

Published: May 05, 2022
Vol/Issue: 41(2)
Pages: 281-299
License: View

Authors

Funding

All-India Institute of Medical Sciences Award: A514

Hamad Medical Corporation Award: 16354/16

Sidra Medicine Precision Program Award: 5081012003

Cite This Article

Tarang Sharma, Ashna Gupta, Ravi Chauhan, et al. (2022). Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis. Cancer and Metastasis Reviews, 41(2), 281-299. https://doi.org/10.1007/s10555-022-10026-6

Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis

You May Also Like